Glycostem Therapeutics is a Netherlands based lifescience company advancing the science of cellular immunotherapy by creating breakthroughs in the expansion and differentiation of hematopoietic stem cells.

Glycostem Therapeutics has developed a new and innovative cell culture system for the ex-vivo generation of clinically relevant amounts of NK-cells.   

Glycostem Therapeutics pursues an open project collaboration policy towards joint development of cellular immunotherapeutics for treatment of leukemia, lymphomas and other forms of cancer.